9:35 AM
Oct 26, 2018
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Intellia CRISPR-Cas9 platform creates gene insertion edits in vivo

Intellia Therapeutics Inc. (NASDAQ:NTLA) presented data at the European Society of Gene and Cell Therapy meeting in Lausanne, Switzerland, showing that its CRISPR-Cas9 platform is capable of creating both gene disruption and the more challenging gene insertion edits in vivo (see "Intellia's Delivery Address").


Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >